ADCT logo

ADCT
Adc Therapeutics SA

1,249
Mkt Cap
$487.14M
Volume
1.84M
52W High
$4.98
52W Low
$1.23
PE Ratio
-3.06
ADCT Fundamentals
Price
$3.68
Prev Close
$3.83
Open
$3.58
50D MA
$4.03
Beta
1.56
Avg. Volume
933,511.33
EPS (Annual)
-$1.12
P/B
-2.49
Rev/Employee
$421,538.86
$626.76
Loading...
Loading...
News
all
press releases
ADC Therapeutics (ADCT) Q4 2025 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets·7h ago
News Placeholder
More News
News Placeholder
Full Transcript: ADC Therapeutics Q1 2026 Earnings Call
read more...
Benzinga·10h ago
News Placeholder
ADC Therapeutics Q1 Earnings Call Highlights
ADC Therapeutics (NYSE:ADCT) reported first-quarter 2026 net product revenue growth for its lymphoma therapy ZYNLONTA and reiterated expectations for multiple upcoming clinical milestones, led by a near-term top-line readout from its Phase 3 LOTIS-5 trial. ZYNLONTA revenue rises to $20 million as c...
MarketBeat·17h ago
News Placeholder
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Beats Revenue Estimates
ADC Therapeutics (ADCT) delivered earnings and revenue surprises of -10.53% and +5.62%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·18h ago
News Placeholder
ADC Therapeutics (NYSE:ADCT) Posts Quarterly Earnings Results, Beats Estimates By $0.06 EPS
ADC Therapeutics (NYSE:ADCT - Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.06. The firm had revenue of $20.85 million during the quarter, compared to analysts...
MarketBeat·19h ago
News Placeholder
ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates
ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates PR...
PR Newswire·19h ago
News Placeholder
Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year?
Here is how ADC Therapeutics SA (ADCT) and Bioventus (BVS) have performed compared to their sector so far this year.
Zacks·4d ago
News Placeholder
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan ADC Therapeutics Makes Grants to New Employees Under Inducement Plan PR Newswire LAUSANNE, Switzerland, May 1, 2026 LAUSANNE...
PR Newswire·4d ago
News Placeholder
ADC Therapeutics (ADCT) Projected to Post Quarterly Earnings on Monday
ADC Therapeutics (NYSE:ADCT) will be releasing its Q1 2026 earnings before the market opens on Monday, May 4. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-4-adc-therapeutics-sa-stock...
MarketBeat·6d ago
News Placeholder
ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026
ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026 ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026 PR Newswire...
PR Newswire·8d ago
<
1
2
...
>

Latest ADCT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.